NEI Podcast

Neuroscience Education Institute
  • 0.0 (0)
  • MEDICINE
  • MONTHLY
NEI Podcast Podcast

The Neuroscience Education Institute (NEI) is committed to help raise the standard of mental health by providing imaginative medical education that focuses on the highest level of learning. Each episode offers an opportunity to learn about current issues in psychiatry from key opinion leaders in the medical field. NEI's Podcast would be of value to anyone with an interest in neuropsychiatric diseases and psychopharmacology.

  1. E234 - Diagnosis, Treatment, and Pathophysiology of Catatonia with Dr. Joan Striebel

    18 SEPT

    E234 - Diagnosis, Treatment, and Pathophysiology of Catatonia with Dr. Joan Striebel

    Join Dr. Andy Cutler as he talks with Dr. Joan Striebel about the syndrome of catatonia, including its dynamic presentation, treating the underlying disorder, and why clinicians must raise their index of suspicion when evaluating symptoms that could indicate catatonia is present.  Dr. Joan Striebel is a psychiatrist at the California Department of State Hospitals, which is the largest forensic mental health hospital system in the nation.    Resources:  Bush-Francis Catatonia Rating Scale Assessment Resources  Catatonia and Its Treatments  Catatonia: A Clinician’s Guide to Diagnosis and Treatment  Catatonia: From Psychopathology to Neurobiology  Guidelines for the management of catatonia    Never miss an episode!🎙 SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter

    56 min
  2. E233 - (CME) Detecting and Treating Bipolar Disorder in Primary Care

    4 SEPT

    E233 - (CME) Detecting and Treating Bipolar Disorder in Primary Care

    In this CME episode, Dr. Andrew Cutler interviews Dr. Charles Vega about the challenges of identifying bipolar disorder in primary care and how to over come them. They also discuss strategies for initiating and managing pharmacological treatment long term in collaboration with patients and psychiatric specialists. Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objective: After completing this educational activity, you should be better able to: Identify the key symptoms and diagnostic criteria for bipolar disorder to accurately screen and diagnose patients presenting in primary care settings Describe strategies for initiating and managing pharmacological treatment of bipolar disorder, including appropriate use of mood stabilizers, antipsychotics, and monitoring for side effects and adherence Explain the role of the primary care provider in coordinating care for bipolar disorder patients, including providing psychoeducation, determining appropriate level of care, and collaborating with mental health specialists when needed Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 45 minutes Released: September 04, 2024*   Expiration: September 03, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-PrimCare Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 0.75 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credits™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 0.75 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 0.75 contact hour (.075 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 0.75 AAPA Category 1 credit. Approval is valid until September 03, 2027. PAs should only claim credit commensurate with the extent of their participation. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation

    47 min
  3. E232 - The PsychopharmaStahlogy Show: Underutilized Psychiatric Drugs: Clozapine with Dr. Jonathan Meyer

    21 AUG

    E232 - The PsychopharmaStahlogy Show: Underutilized Psychiatric Drugs: Clozapine with Dr. Jonathan Meyer

    What are the primary barriers to clozapine utilization in the United States, and how do these barriers impact patient care? What are some common misconceptions or negative attitudes among prescribers regarding clozapine, and how can these be addressed? What are some effective strategies for improving the management of clozapine’s side effects to encourage its use? What strategies can be implemented to improve education and awareness about clozapine?  Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on underutilized psychotropic drugs.  Today, Dr. Andy Cutler interviews Dr. Jonathan Meyer and Dr. Stephen Stahl about factors that have led to the underutilization of clozapine in psychiatry.  Let’s listen to Part 3 of our theme: Underutilized Psychiatric Drugs.  Subscribe to the NEI Podcast, so that you don’t miss another episode!  Resources  The Clozapine Handbook   Clozapine titrations paper (see Supplementary Material):   de Leon J et al. Pharmacopsychiatry 2022;55(2):73-86.  FDA committees meeting to discuss reevaluation of the Clozapine REMS program (November 19, 2024): click here.

    52 min
  4. E231 - The 2023 NEI Congress Young Investigator Poster Competition #1 Poster with Dr. Richard Price

    7 AUG

    E231 - The 2023 NEI Congress Young Investigator Poster Competition #1 Poster with Dr. Richard Price

    Join Dr. Andy Cutler as he talks with the co-author of the winning poster from the 2023 NEI Congress Young Investigator Poster Competition, Dr. Richard Price. They discuss the objectives, design, and key findings of the poster titled, “Improved Mood and Weight Gain Mitigation Following Switch from Aripiprazole to Cariprazine.” They also discuss the potential implications of these findings and applications of cariprazine in psychiatry.  Dr. Richard Price is an Assistant Professor of Clinical Psychiatry at Weill Cornell Medical College. Maxwell Zachary Price, the lead author of the winning poster, is a medical student at Hackensack Meridian School of Medicine.  Learn about upcoming NEI Meetings at https://nei.global/meetings

    50 min
  5. E230 - The PsychopharmaStahlogy Show: Underutilized Psychiatric Drugs: MAOIs with Dr. Thomas Schwartz

    17 JUL

    E230 - The PsychopharmaStahlogy Show: Underutilized Psychiatric Drugs: MAOIs with Dr. Thomas Schwartz

    What are the main reasons MAOIs are underutilized in psychiatric practice despite their proven efficacy for certain conditions? What are the key dietary restrictions patients must follow when taking MAOIs? What are the critical drug-drug interactions clinicians must be aware of when prescribing MAOIs? What clinical pearls or tips would you give to clinicians looking to become more comfortable using these agents?  Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on underutilized psychotropic drugs.  Today, Dr. Andy Cutler interviews Dr. Thomas Schwartz and Dr. Stephen Stahl about factors that have led to the underutilization of MAOIs in psychiatry.  Let’s listen to Part 2 of our theme: Underutilized Psychiatric Drugs.  Subscribe to the NEI Podcast, so that you don’t miss another episode!  Resources  Email roundtable@maoiexperts.topicbox.com for guidance on prescribing MAO inhibitors  The Prescriber's Guide to Classic MAO Inhibitors (Phenelzine, Tranylcypromine, Isocarboxazid) for Treatment-Resistant Depression  Practical Guide for Prescribing MAOIs: Debunking Myths and Removing Barriers

    52 min
  6. E229 - Treatment Approaches for Smoking Cessation in the LGBTQIA+ Community with Dr. Rhonda Schwindt

    3 JUL

    E229 - Treatment Approaches for Smoking Cessation in the LGBTQIA+ Community with Dr. Rhonda Schwindt

    What are the current smoking rates among LGBTQIA+ individuals compared to the general population? What unique barriers do LGBTQIA+ individuals face when trying to quit smoking? What are the recommended pharmacotherapies and behavioral interventions for smoking cessation? What training is needed for providers to deliver culturally affirmative smoking cessation treatment for LGBTQIA+ patients?  Dr. Rhonda Schwindt is an Associate Professor at The George Washington University School of Nursing. She is a nationally certified Psychiatric-Mental Health Nurse Practitioner with an active clinical practice specializing in LGBTQIA+ health, trauma, and treatment-resistant mood disorders. Dr. Schwindt earned a Doctor of Nursing Practice degree from Case Western Reserve University, a Master of Science in Nursing from Indiana University School of Nursing, a Bachelor of Arts from Purdue University, and a diploma in nursing from St. Elizabeth School of Nursing. Dr. Schwindt has a funded program of research focused on improving health outcomes for the LGBTQIA+ community. She led a team of researchers that examined barriers to, and facilitators of, smoking cessation and treatment utilization in the transgender and gender expansive population as well as studies exploring best practices for teaching graduate students how to provide affirming care. Dr. Schwindt has received international recognition as an outstanding graduate nurse educator and for clinical excellence in the care of persons living with serious mental illness.  Resources  Pride in Being Tobacco-Free  UCSF Smoking Cessation Leadership Center  Fenway Health  Trevor Project

    1h 3m
  7. E228 - (CME) Tardive Dyskinesia Today: Updates in the Current Landscape of Tardive Dyskinesia

    26 JUN

    E228 - (CME) Tardive Dyskinesia Today: Updates in the Current Landscape of Tardive Dyskinesia

    In this CME episode, Dr. Andrew Cutler interviews Dr. Laxman Bahroo about the current landscape of tardive dyskinesia, including screening, diagnosis, and treatment. Practical strategies based on the latest data are reviewed at length, particularly for long-term management of tardive dyskinesia.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Consider the individual patient profile and symptoms when determining a treatment plan for patients with tardive dyskinesia Integrate latest safety, efficacy, and tolerability data of VMAT2 inhibitors into decision-making processes when considering treatment options for tardive dyskinesia Evaluate practical strategies for patient follow-up and long-term VMAT2 inhibitor treatment Evaluate and integrate recent updates and advancements regarding evidence-based treatment strategies for tardive dyskinesia Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit. Estimated Time to Complete: 1 hour Released: June 26, 2024*   Expiration: June 25, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-02-TD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hours Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEUs). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until June 25, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office main

    1h 7m
  8. E227 - The PsychopharmaStahlogy Show: Underutilized Psychiatric Drugs: Lithium with Dr. Jonathan Meyer

    19 JUN

    E227 - The PsychopharmaStahlogy Show: Underutilized Psychiatric Drugs: Lithium with Dr. Jonathan Meyer

    What are the properties of lithium that make it a unique treatment option? What are the main reasons why lithium is underutilized in clinical practice, and what are the consequences of underutilization? What are the common myths or misconceptions about lithium’s safety and tolerability? How can we better educate patients about the benefits of lithium and address concerns about side effects or monitoring requirements that may impact adherence?  Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on underutilized psychotropic drugs.  Today, Dr. Andy Cutler interviews Dr. Jonathan Meyer and Dr. Stephen Stahl about factors that have led to the underutilization of lithium in psychiatry.  Let’s listen to Part 1 of our theme: Underutilized Psychiatric Drugs.  Subscribe to the NEI Podcast, so that you don’t miss another episode!    Resource  The Lithium Handbook

    1h 4m
See All (235)

About

The Neuroscience Education Institute (NEI) is committed to help raise the standard of mental health by providing imaginative medical education that focuses on the highest level of learning. Each episode offers an opportunity to learn about current issues in psychiatry from key opinion leaders in the medical field. NEI's Podcast would be of value to anyone with an interest in neuropsychiatric diseases and psychopharmacology.

Information

  • Creator
    Neuroscience Education Institute
  • Years Active
    2008 - 2024
  • Episodes
    235
  • Rating
    Clean
  • Copyright
    Copyright © Neuroscience Education Institute. All rights reserved.
  • Show Website
    NEI Podcast

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada